Analysts spotlight the winners — and losers — on ASCO preview night
ASCO 2019 got started with a bang on Wednesday night as a handful of biotechs coordinated a series of abstract drops and statements updating analysts and investigators on their data for some closely watched drugs. The big news still awaits us in Chicago, but some early snapshots on results have whipped up some fervor for — and against — some of the biotechs making the trip.
MacroGenics emerges as the star of the abstract show
One of the big winners was MacroGenics $MGNX, which updated the oncology world on margetuximab, its Fc engineered anti-HER2 antibody for breast cancer. The abstract and a release noted a particular success for a subset of patients, though it’s a very, very big subset.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.